

# Bromodomain Containing Protein 3 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/BB9833735CB6EN.html>

Date: December 2019

Pages: 68

Price: US\$ 2,625.00 (Single User License)

ID: BB9833735CB6EN

## Abstracts

Bromodomain Containing Protein 3 - Pipeline Review, H2 2019

### SUMMARY

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets.

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease),

Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer and Systemic Lupus Erythematosus.

The latest report Bromodomain Containing Protein 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)

The report reviews Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics and enlists all their major and minor projects

The report assesses Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics based on mechanism of action (MoA), route of

administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Overview

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Companies

Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Oncopria Therapeutics LLC

Zenith Epigenetics Ltd

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Drug Profiles

ABBV-744 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-95775 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NHWD-870 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-19796 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-20798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by AbbVie Inc, H2 2019  
Pipeline by Amgen Inc, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Constellation Pharmaceuticals Inc, H2 2019  
Pipeline by Ningbo Wenda Pharma, H2 2019  
Pipeline by Oncopia Therapeutics LLC, H2 2019  
Pipeline by Zenith Epigenetics Ltd, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

### COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Oncopia Therapeutics LLC

Zenith Epigenetics Ltd

## I would like to order

Product name: Bromodomain Containing Protein 3 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/BB9833735CB6EN.html>

Price: US\$ 2,625.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BB9833735CB6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970